Coronaria Hoiva acquired by Humana

FINLAND Health Providers / Healthcare Facilities / Nursing Homes EV €50–150M

Context

Humana AB entered into a definitive agreement to acquire 100% of Coronaria Hoiva Oy to significantly expand its operational footprint in the Finnish market. This strategic acquisition was designed to integrate Coronaria Hoiva’s specialized residential care portfolio into Humana’s existing Finnish operations, creating a more diversified and robust platform for social care delivery. The transaction was financed through a combination of existing cash reserves and new credit facilities, and it received formal approval from the Finnish Competition and Consumer Authority in early April. The move aligned with Humana’s long-term strategy of consolidating the Nordic care market, providing an immediate positive contribution to the group's revenues and earnings per share while enhancing its ability to serve the growing Finnish aging population.

Coronaria Hoiva, which reported an EBITDA margin of [members only] in 2020, is valued in this transaction at an EV/EBITDA multiple of 15x–25x, representing a premium to the average observed in the Healthcare & Pharma sector (14.3x in 2019).

-> Deep-dive in Healthcare & Pharma market trends

Target

Coronaria Hoiva Oy functions as a prominent Finnish provider of social care services, specializing in residential care for the elderly, individuals with disabilities, and mental health rehabilitation. At the time of the transaction, the company operated a high-quality network of care homes across Finland, maintaining a strong reputation for clinical excellence and personalized service delivery.

Ent. Value

€50–150M

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

15x–25x

EV / EBIT

[members only]

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2020

2019

Similar deals in Health Providers

Similar deals in Health Providers
Date	Acquirer	Target	Country	Sector
04/2019	COLISÉE	ARMONEA	BELGIUM	Nursing Homes
03/2019	DOMUSVI	RESIDALYA	FRANCE	Nursing Homes
11/2018	DENTALPRO	CLINIODENT	SWITZERLAND	Dental Centers
04/2018	INVESTINDUSTRIAL	LIFEBRAIN	ITALY	Labs (Biology)
03/2018	ICV PARTNERS	OUTPATIENT IMAGING AFFILIATES	UNITED STATES	Radiology
03/2018	THE ADOLFSEN GROUP	FRÖSUNDA	SWEDEN	Healthcare Facilities
01/2018	PERMIRA	I-MED RADIOLOGY NETWORK	AUSTRALIA	Radiology
06/2017	ICG / MANAGEMENT & PRIVATE INVESTORS	DOMUSVI	FRANCE	Nursing Homes
05/2017	BC PARTNERS	DENTALPRO	ITALY	Dental Centers
04/2017	EQT PARTNERS	COLISÉE	FRANCE	Nursing Homes

REFERENCES

Valuation range: EV €50–150M

Revenue range: €50–100M

EBITDA range: €0–5M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 15x - 25x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Coronaria Hoiva by Humana are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: humana

FAQ

What transaction does this page cover?

This page covers Humana’s acquisition of 100% of Coronaria Hoiva, a Finnish company specialised in Healthcare Facilities, in 2019.

How was the acquisition of Coronaria Hoiva by Humana valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €50–150M band, its EV/EBITDA multiple within the 15x - 25x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Coronaria Hoiva’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Coronaria Hoiva generated annual revenue estimated in the €50–100M range and EBITDA in the €0–5M bracket (FY 2020). Detailed financial figures are available to members.

How does the valuation of Coronaria Hoiva compare to benchmarks in the Healthcare & Pharma sector?

With an estimated valuation multiple in the range of 15x - 25x, Coronaria Hoiva trades above the median sector multiple of 14.3x observed for the Healthcare & Pharma sector in 2019. The descriptive comparison is based on 15 transactions with available EV/EBITDA multiples from differences in size, growth, profitability that may affect comparability.

What sources support the information on this transaction?

Transaction data and operational intelligence were compiled from independent financial press reporting by specialized M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.